EUVIMEDEUVIMED entdecken
BeobachtungsstudieMultizentrische StudieOpen Access · CC BY 4.0

Kidney Function Decline in Sickle Cell Disease

Kabir O Olaniran, Alecia C Nero, Orson W Moe iD, Robert D Toto iD, S Susan Hedayati iD

Kidney360 · 2026

DOI: 10.34067/kid.0000001116 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Kidney360, 2026. Verfasst von Kabir O Olaniran und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas. Hauptthemen laut MEDLINE: Anemia, Sickle Cell, Glomerular Filtration Rate, Renin-Angiotensin System, Angiotensin-Converting Enzyme Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCATS NIH HHS, National Center for Advancing Translational Sciences of the National Institutes of Health under the University of Texas Southwestern Medical Center Clinical an….

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Key Points Renin-angiotensin system inhibitor use was not associated with slowed GFR decline in sickle cell disease. This null association did not change after excluding low-dose renin-angiotensin system inhibitors or including an interaction term with sickle cell disease therapies. Our findings highlight the limitations of real-world data and underscore the urgent need for prospective trials and novel therapeutics.

Background

Sickle cell disease (SCD) is associated with accelerated kidney function decline, with no proven effective therapies. We examined the associations between treatment with renin-angiotensin system inhibitors (RASi) and eGFR decline in SCD.

Methods

This two-center observational study used electronic health record data of adult, Black patients with SCD (by hemoglobin electrophoresis), and ≥1-year follow-up between 2010 and 2024. We compared incident RASi users (exposure) to no treatment (reference). We created 1:1 propensity score-matched cohorts, balancing on demographics, vital signs, comorbidities, medications, and laboratory values. The primary end point was the difference in the mean change in eGFR per year, analyzing only chronic slopes (≥90 days postindex date) using linear mixed models on the matched cohorts. Sensitivity analyses were performed excluding patients with missing albuminuria and excluding low-dose RASi. Effect modification by SCD-modifying therapies was also examined.

Results

Matched cohorts identified were primary analysis (358 patients), excluding missing albuminuria data (262 patients), and excluding low-dose RASi (270 patients). All cohorts achieved optimal standardized mean differences 0.05.

Conclusions

In this large, real-world cohort of patients with SCD, RASi use was not associated with slowed eGFR decline. These findings underscore the limitations of observational data and highlight the urgent need for prospective trials to identify effective GFR-preserving therapies for this high-risk population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anemia, Sickle CellGlomerular Filtration RateRenin-Angiotensin SystemAngiotensin-Converting Enzyme InhibitorsKidneyAngiotensin Receptor AntagonistsHumansFemaleMaleAdultMiddle Aged

Stichwörter der Autor:innen

renal function declinerenin-angiotensin system

Substanzen

Angiotensin-Converting Enzyme InhibitorsAngiotensin Receptor Antagonists

Autor:innen und Institutionen

  • Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas.
  • Department of Physiology, University of Texas Southwestern Medical Center, Dallas, Texas.
  • Charles and Jane Pak Center for Mineral Metabolism and Clinical Research, University of Texas Southwestern Medical Center, Dallas, Texas.
  • Department of Population and Data Sciences, Peter O'Donnell Jr. School of Public Health, University of Texas Southwestern Medical Center, Dallas, Texas.
  • Department of Medicine, Stony Brook University, Stony Brook, New York.

ORCID-Profile: Orson W Moe, Robert D Toto, S Susan Hedayati

Förderung

  • NCATS NIH HHS
  • National Center for Advancing Translational Sciences of the National Institutes of Health under the University of Texas Southwestern Medical Center Clinical an…

Zitieren

APA

Olaniran, K. O., Nero, A. C., Moe, O. W., Toto, R. D., & Hedayati, S. S. (2026). Kidney Function Decline in Sickle Cell Disease. Kidney360. https://doi.org/10.34067/kid.0000001116

Vancouver

Olaniran KO, Nero AC, Moe OW, Toto RD, Hedayati SS. Kidney Function Decline in Sickle Cell Disease. Kidney360. 2026. doi:10.34067/kid.0000001116

BibTeX
@article{Olaniran2026,
  author = {Olaniran, Kabir O and Nero, Alecia C and Moe, Orson W and Toto, Robert D and Hedayati, S Susan},
  title = {Kidney Function Decline in Sickle Cell Disease},
  journal = {Kidney360},
  year = {2026},
  doi = {10.34067/kid.0000001116}
}
Kostenlos starten →